Biomarkers for Brain Disorders: Challenges and Opportunities

27 February–2 March 2011

This exciting new Wellcome Trust Scientific Conference will discuss methodological aspects of biomarker identification across a spectrum of psychiatric and neurodegenerative disorders, strategies for diagnostic assay development and pathways for regulatory approval. Specific attention will be given to results from consortia such as the Alzheimer Disease Neuroimaging Initiative (ADNI), and to the prioritization of approaches not yet included in large consortia efforts, such as functional measures of brain activity captured by fMRI or electrophysiological recordings.

Topics:

• Strategies for building large biorepositories

• Technologies for molecular profiling and biomarker discovery: is multimodality the key?

• Building and validating biochemical and functional assays

• Measuring brain function in health and disease

• Clinical studies of biomarkers in neurological disease (e.g. Amyotrophic lateral sclerosis, Multiple sclerosis, schizophrenia, Alzheimer’s, Parkinson’s disease, and other CNS indications)

• Paths for regulatory approval

Abstract deadline: 17 January 2011

Registration deadline: 24 January 2011

Courses and Conferences are held at the Wellcome Trust Genome Campus, Hinxton, Cambridge – home to one of the world’s largest concentrations of expertise in genomics and bioinformatics. For full details, please visit, www.wellcome.ac.uk/conferences

About  |  Contact
	OVERVIEW SPEAKERS AGENDA
			Develop winning translational strategies to improve drug candidate survival What is your definition of Translational Medicine and how can we bring it to the next level? How is your individual Translational Medicine model affecting discovery and development efforts? Does your company embrace Translational Medicine inherently, adopt it with broad brush strokes because it is in vogue or ignore it altogether? I can guarantee that your answer will be completely different to everybody else who is reading this and therein lies the rub. Despite the diversity of opinion in this space, the overriding premise remains the same: How to translform from blockbuster to nichebuster and the potential of drug dependent biomarkers. What are the options for partnering to make things happen? What is required from the business and regulatory side to make this work? How to make biomarker driven treatment choices. The value and practical solutions for biomarkers in translational medicine. Find successful organizational collaborations for the development of drug dependent biomarkers. This meeting will not be a best practice conference with standard speaking slots and power point presentations. Yes, we have leading thinkers in this space on our speaker panel – but delegates in attendance will be as much a part of the meeting as these speakers. Discussion, debate and scrutiny will be the order of the meeting. This is your chance to be part of an Initiative to test theories, discuss successful models and collaborations and ultimately use the take-aways from these discussions to take your Discovery and Development process to the next level. Anybody with a real interest and passion for Translational Medicine will benefit from being involved so click here to be kept updated on developments.